These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 6739892)

  • 1. [Structural aspects of the kidney in experimental atheromatosis].
    Lasierra J; Sánchez Casajús A; Martínez Peñuela JM; Velázquez E
    Rev Clin Esp; 1984 Apr; 173(1):15-9. PubMed ID: 6739892
    [No Abstract]   [Full Text] [Related]  

  • 2. [Activity of ticlopidine and lysine acetylsalicylate in experimental atheromatosis. Effects on the production of PGI2].
    Lasierra J; Viladés E; Fernández A; Díez M; Gil M; Velázquez E
    Arch Farmacol Toxicol; 1985 Aug; 11(2):109-16. PubMed ID: 3936423
    [No Abstract]   [Full Text] [Related]  

  • 3. Experimental model of venous thrombosis in rats and effect of some agents.
    Kumada T; Ishihara M; Ogawa H; Abiko Y
    Thromb Res; 1980 Apr 1-15; 18(1-2):189-203. PubMed ID: 7404498
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of the fibrinolytic system in experimental atheromatosis].
    Lasierra J; Díez MM; Capetillo MA; Viladés E; Gracia A; Aznar López J; Piñero J; López Campos JL; Bermudo F; Cobo R
    Sangre (Barc); 1982; 27(6):1018-29. PubMed ID: 6764034
    [No Abstract]   [Full Text] [Related]  

  • 5. [Changes in mucopolysaccharides and ultrastructural alterations in experimental atheromatosis].
    López-Campos JL; Piñero J; Lasierra J; Navas P; Moreno J; Cobo R
    Rev Clin Esp; 1982 Apr; 165(1):15-21. PubMed ID: 6214825
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological studies on ticlopidine, a new platelet aggregation inhibitor. Part I: Cardiovascular effects.
    Akashi A; Tamura K; Hirohashi M; Watanabe K; Kasahara A
    Arzneimittelforschung; 1980; 30(3):409-14. PubMed ID: 7387750
    [No Abstract]   [Full Text] [Related]  

  • 7. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets.
    Lee H; Paton RC; Ruan C; Caen JP
    Thromb Haemost; 1981 Oct; 46(3):590-2. PubMed ID: 6797089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of ticlopidine and lysine acetylsalicylate on fibrinolytic activity of the arterial wall in experimental atherosclerosis].
    Lasierra J; Díez MM; Fernández A; Viladés E; Gil M; Velázquez E
    Arch Farmacol Toxicol; 1984 Dec; 10(3):161-6. PubMed ID: 6442550
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
    Kohga S; Kinjo M; Tanaka K; Ogawa H; Ishihara M; Tanaka N
    Cancer Res; 1981 Nov; 41(11 Pt 1):4710-4. PubMed ID: 7306988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
    Andriani A; Chiappetta MG; Fabiani M; Mosiello G; Beni A
    Clin Ter; 1983 Feb; 104(3):219-22. PubMed ID: 6345050
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiaggregant effect of ticlopidine in atherosclerotic patients.
    Manotti C; Potì R; Megna A; Poli T; Alberani M
    Farmaco Prat; 1982 Oct; 37(10):325-30. PubMed ID: 7140941
    [No Abstract]   [Full Text] [Related]  

  • 12. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effects of ticlopidine on platelet aggregation: study on 13 atherosclerotic patients].
    Lenci R; Galante A; Borzi M; Ariganello M; Sommariva L; Filice A; Cannata D
    Clin Ter; 1983 Feb; 104(3):205-9. PubMed ID: 6861457
    [No Abstract]   [Full Text] [Related]  

  • 14. [Migraine or transient ischemic attacks in a patient with essential thrombocythaemia. Treatment with ticlopidine (author's transl)].
    Bousser MG; Conard J; Lecrubier C; Bousser J
    Ann Med Interne (Paris); 1980; 131(2):87-90. PubMed ID: 7396326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ticlopidine as something more than a platelet antiaggregant].
    Villaverde C; Cánovas M; Padró T; Navarro C
    Arch Farmacol Toxicol; 1984 Aug; 10(2):121-32. PubMed ID: 6517621
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia.
    Hohlfeld T; Scharnowski F; Braun M; Schrör K
    Thromb Haemost; 1994 Jan; 71(1):112-8. PubMed ID: 7513092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticlopidine and adenylate cyclase.
    Bonne C; Battais E
    Agents Actions Suppl; 1984; 15():88-96. PubMed ID: 6592947
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experimental study of the effect of ticlopidine chlorhydrate on the development of atherosclerotic lesions].
    Viver Manresa E; Huguet Redecilla P
    Angiologia; 1986; 38(3):134-49. PubMed ID: 3740536
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitory effects of ticlopidine on platelet function as assessed by three different methods.
    Cuyun-Lira O; Kaneko M; Takafuta T; Satoh K; Ohnishi M; Yatomi Y; Ozaki Y
    Eur J Pharm Sci; 2007 Jan; 30(1):21-5. PubMed ID: 17070023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
    Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.